在ADPKD患者中抑制SGLT2 - 填补证据差距
Roman-Ulrich Müller1,2,3, Dominique Guerrot4, Michel Chonchol5
1Department II of Internal Medicine, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.
概括
-葡萄糖共运输体2抑制剂 (SGLT2i) 提供了除了糖尿病之外的保护. 本综述探讨了它们在自体主导多囊性病 (ADPKD) 中的潜在用途,强调了临床试验的必要性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共传输体2抑制剂 (SGLT2i) 在慢性病 (CKD) 中表现出保护作用,独立于血糖控制.
- 自体主导多囊性病 (ADPKD) 是最常见的遗传性病,缺乏有效的治疗选择.
- 关键患者群体,包括ADPKD患者,被排除在关键SGLT2i试验之外.
研究的目的:
- 审查在ADPKD患者中SGLT2i的当前知识.
- 确定需要进行临床试验来评估SGLT2i在ADPKD中的疗效和安全性.
- 概述在ADPKD中SGLT2i正在进行和即将进行的临床试验.
主要方法:
- 对ADPKD中SGLT2i的临床前和临床数据的文献综述.
- 分析现有的临床试验数据,识别知识缺口.
- 目前和计划中的临床试验的总结,调查ADPKD中的SGLT2i.
主要成果:
- 在ADPKD中SGLT2i的临床前数据是不确定的.
- 在ADPKD中缺乏SGLT2i的临床疗效数据.
- 潜在的疾病特异性安全问题需要进一步调查.
结论:
- 对于ADPKD来说,SGLT2i是一个有前途的治疗途径.
- 迫切需要进行足够的临床试验,以确定SGLT2i在ADPKD中的有效性和安全性.
- 目前和未来的试验旨在提供SGLT2i在ADPKD患者中使用的证据.
相关概念视频
Glucose Transporters
22.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.2K
Dipeptidyl Peptidase 4 Inhibitors
139
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
139
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
126
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
126
Secondary Active Transport
6.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.6K
Glucose Absorption Into the Small Intestine
31.0K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.0K
Oral Hypoglycemic Agents: Glinides
112
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
112


